Biosimilar Ranluspec is used to treat neovascular (wet) age-related macular degeneration and other retinal vascular disorders ...
Sandoz has started construction for a new, state-of-the-art biosimilars production center for sterile product manufacturing in Brnik, Slovenia. This $440 million project brings the company’s total ...
Evotec’s biologics manufacturing unit, dubbed Just – Evotec Biologics, has expanded its multiyear biosimilar deal with Sandoz that the partners initially inked in May 2023. As part of the pact, Sandoz ...
Basel, July 1, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the start of construction for a new, state-of-the-art biosimilars production ...
In a bid to boost its presence in the lucrative biosimilar space, Sandoz has signed a non-binding agreement to buy Evotec Biologics’ manufacturing site in Toulouse, France. By acquiring contract ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...
The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med Tysabri. After waiting in the wings post-FDA approval in 2023, Sandoz’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results